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cancers showed no vessel invasion or positive cytology results. There 
was no correlation between tumor size, TDR, and subtype. No mortal-
ity or recurrence has occurred, but one patient developed postoperative 
pneumothorax.
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Introduction: Pancoast tumors are seen as a subgroup of lungcancer 
that behave differently from most other non small cell lungcancers. 
These tumors tend to behave more aggressively locally and metastasize 
more rapidly. Therefore their treatment should also be more aggressive. 
Our center’s experience with Pancoast tumors will be discussed and 
compared with current literature to asses the effects of induction 
chemoradiotherapy on the outcome. Based on these results a proposal 
for treatment will be advocated.
Methods: We retrospectively analyzed the records of all patients with 
Pancoast tumors treated with a multimodality approach at our institu-
tion from july 2001 through January 2007 and compared them with 
recent literature. 
Results: Twenty-six patients were in the study cohort. Because two 
patients failed to receive both chemotherapy and radiotherapy, we 
eventually included 24 patients (7 women, 17 men). The mean age was 
60 years (range, 40-78 years)
There were 18 patients with T3 tumors. 7 patients were proven N2 
positive after a positive PET scan and following mediastinoscopy. 
The chemotherapy regimens consisted of gemcitabine+carboplatin or 
etoposide+carboplatin. Chemotherapy was concurrently or sequentially 
given with external beam radiotherapy delivered in daily fractions 
for a total dose of 46 Gy in most patients. 7 patients with N2 disease 
underwent re-mediastinoscopy after completed induction therapy, with 
all proven negative N2 lymph nodes. 
Postoperative complications occurred in 8 patients (36 without any 
postoperative mortality. Although in 8 patients (36%) there was still vi-
able tumor in the pathologic specimen, we achieved complete resection 
in all patients but 1. There were no positive N2 nodes in the deﬁni-
tive pathologic specimen. In 2 patients with N2 positive nodes before 
induction therapy, there were postoperative positive N1 nodes in the 
specimen. Mean length of follow-up was 19 months (2-58). 6 patients 
died, 2 patients because of locoregional recurrence, 3 patients due to 
metastasis and 1 patient died of cardial cause. 4/12 patients with a fol-
low-up of more than two years died as a result of recurrent malignancy. 
Conclusions: Preoperative Chemo-Radiotherapy results in a high 
percentage of radical resections. Postoperative complications are more 
frequent. The subgroup of patients with a >2 year follow up show high 
survival rates of 66% especially when compared to patients in literature 
that have been treated with surgery alone. The overall results are 
comparable to results reported in literature. Tumor positive mediastinal 
lymph nodes before treatment should not necessarily exclude patients 
from trimodality treatment. The improved survival rates compared to 
surgery alone make this treatment the treatment of choice. 
Therefore we advocate that in this group of patients early multidisci-
plinary staging and organization of treatment is mandatory.
P3-278 NSCLC: Surgery Posters, Wed, Sept 5 – Thur, Sept 6 
Effect of neoajuvant chemotherapy in surgery and around surgery 
of patients
Zhang, Yi 
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Background: The aim of this study was to assess feasibility and ef-
ﬁcacy of neoajuvant chemotherapy with NVB and carboplatin followed 
surgery for patients with stage III NSCLC. 
Methods: We report 27 consecutive patients with all staged III NSCLC 
receiving neoadjuvant therapy. mean age was 62.1 years. Cell type was 
squamous 17 cases, adenocarcinoma 7 cases, adenosquamous 3 cases. 
Operations included pneumonectomy(10), pneumonectomy plus ca-
rino-resection(1), bilobectomy(2), lobectomy(10), lobectomy plus lung 
artery plastics(1), exploration(3). Chemotherapy was NP or NC for 1-2 
cycle before surgery. All patients were gived 4-6 cycles chemotherapy 
after operation.
Results: In this group, CR 1, PR 12, SD 13, PD 1.The rate of resection 
was 88.9%. 3 cases of exploration due to tumor invasive heart, cava 
venous. No surgical complication and mortality rate. Bleeding during 
operation was 150-4500ml. 
Conclusion: Destination of neoajuvant chemotherapy is down-stage, 
improving complete resection rate, killing micro-tumor of body, avoid-
ing relapse and distant metastasis, prolong survival and improving 
life quality of patients. Therefore, from our group and foreign papers, 
neoajuvant chemotherapy is safe, effective, not increasing surgical 
mortality and complication after operation.
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Purpose: To assess the results of the surgical treatment of patients with 
non-small cell lung cancer (NSCLC) invading the pulmonary vessels or 
atrium.
Methods: From November 1986 to December 2006, 49 patients 
underwent ñombined pneumonectomy with partial resection of the 
left atrium for lung cancer, without (n=41) and with cardiopulmonary 
bypass and reconstruction bovine pericardium graft (n=8).
Results: Of the 49 patients (median age of 58,6 years, range 41 to 75 
years), 47 were men (96%) and 2 were women. Pathologic analysis of 
the specimens identiﬁed 26 patients (53%) with N2 disease, 22 patients 
(45%) with N1 disease, and 1 patient with N0 disease. The T status 
was pT4 in 35 patients, pT3 in 14 patients. The myocard in border of 
resection was detected by microscopy. Histology was squamous cell 
carcinoma in 37 patients, adenocarcinoma in 4, large cell carcinoma 
in 2, mucoepidermoid carcinoma in 1 and adenoid cystic carcinoma in 
1. 8 patients received a preoperative chemotherapy (n = 2) or radio-
therapy (n = 6). 31 patients (63,2%) underwent right pneumonectomy. 
Only left atrium was resected in 34 patients, two organs in 10 patients, 
and three organs in 5 patient. The superior vena cava was resected in 2 
patients, muscular coat of esophagus in 3, the adventitia of the aorta in 
3, the trachea in 9, diaphragma in 1 and the pulmonary artery in 2. The 
operative mortality rate was 6,6% (n = 3). Non-fatal major complica-
tions occurred in 6 patients (12,2%). The survival rate, calculated with 
the Kaplan-Meier method, was estimated as 61% at 1 year, 36 % at 3 
years and 24% at 5 years (median 15 months), including the operative 
